MMR-vaccine

Phase 3Vaccine

GSK

MMR-vaccine is one of 50 biologic programs targeting Chickenpox. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxActive, not recruiting

COVID-19Active, not recruiting

ChickenpoxPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

MMR-vaccine

GSK

Phase 3

1 3

Singulair

AstraZeneca

Preclinical

1 4

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Nadroparin

GSK

Preclinical

1 7

Piperacillin/tazobactam

Pfizer

Preclinical

1 8

Orap

Teva

Preclinical

1 9

Calcium

Eli Lilly

Preclinical

—10

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Chickenpox

NCT06855160

Q2 2027

Phase 3Recruiting

Chickenpox

NCT06806137

Phase 3Recruiting

Chickenpox

NCT06740630

Q2 2031

Post-ApprovalNot yet recruiting

Study completion

NCT06920069

Clinical

Trials by Indication[1]

Immunogenicity4 trials

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

Completed·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 4·NCT01777529·240 enrolled

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Completed· Sanofi logo

Sanofi·Phase 3·NCT03547271·1,660 enrolled

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01553279·284 enrolled

Show 1 more trial

Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children

Completed·SSerum Institute of India Pvt. Ltd.·Phase 4·NCT02253407·341 enrolled

Chickenpox3 trials

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06740630·1,840 enrolled

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06806137·600 enrolled

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06855160·900 enrolled

Chikungunya1 trial

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

Completed·TThemis Bioscience GmbH·Phase 2·NCT03101111·34 enrolled

COVID-191 trial

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 3·NCT04475081·50 enrolled

Immunity1 trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Completed·—··NCT00962819·74 enrolled

3 more indications

Vaccines1 trial

Live Vaccines and Innate Immune Training in COPD.

Completed·JJosefin Eklöf·Phase 4·NCT06257212·60 enrolled

Genital Warts1 trial

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

Unknown status·—·Phase 3·NCT03853785·45 enrolled

Unspecified2 trials

Study of Concomitant Administration of the sIPV and DTaP or MMR

Not yet recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 4·NCT06920069·2,640 enrolled

Zambia SiVET MMR Tdap-IPV

Completed·EEmory University·Phase 1/2·NCT02589678·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for MMR-vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MMR-vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MMR-vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

MMR-vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2031

Trials by Indication[1]

Immunogenicity4 trials

Chickenpox3 trials

Chikungunya1 trial

COVID-191 trial

Immunity1 trial

Vaccines1 trial

Genital Warts1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News